Horizon Technology provides $50 million loan facility to Pelthos
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics
January 15, 2026 4:10 PM ESTFARMINGTON, Conn.--(BUSINESS WIRE)-- Horizon Technology Finance Corporation (NASDAQ: HRZN) (Horizon) (the Company), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (Pelthos), with an initial funding of $30 million, and up to $20 million to support future growth.
Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI (berdazimer) topical gel, an FDA-approved treatment of molluscum contagiosum, a common skin infection characterized by small bumps or lesions. ZELSUVMI delivers nitric oxide... More
